Stock Events

Stock Events

Cellectar Biosciences 

$2.34
54
+$0.11+4.93% Monday 20:00

Statistics

Day High
2.44
Day Low
2.27
52W High
12
52W Low
2.2
Volume
166,827
Avg. Volume
-
Mkt Cap
7.47M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

19AugExpected
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Next
-4.9
-3.29
-1.68
-0.07
Expected EPS
-0.483333
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
0Revenue
-89.16MNet Income

Analyst Ratings

10.00Average Price Target
The highest estimate is 10.00.
From 2 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow CLRB. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Adc Therapeutics SA
ADCT
Mkt Cap133.55M
ADC Therapeutics focuses on developing antibody-drug conjugates for cancer treatment, directly competing with Cellectar's cancer-targeting therapies.
Allogene Therapeutics
ALLO
Mkt Cap655.79M
Allogene Therapeutics works on allogeneic CAR T cell therapies, a different but competing approach in the broader cancer treatment landscape against Cellectar's offerings.
Gilead Sciences
GILD
Mkt Cap155.93B
Gilead Sciences, through its acquisition of Kite Pharma, competes in the oncology space, particularly in cell therapies that could be alternatives to Cellectar's treatments.
Novartis
NVS
Mkt Cap292.07B
Novartis offers a broad range of oncology treatments, including targeted therapies and cell therapy products that compete with Cellectar's cancer treatments.
AMGEN
AMGN
Mkt Cap191.7B
Amgen's extensive portfolio in oncology, including biosimilars and novel therapeutics, positions it as a competitor across various aspects of cancer treatment, challenging Cellectar's market.

About

Cellectar Biosciences is a biopharmaceutical firm engaged in the research, development, and market introduction of therapeutic agents to combat cancer. The company's primary asset is CLR 131 (iopofosine I-131), a phospholipid drug conjugate (PDC), which is currently undergoing several clinical evaluations. It is in Phase 2 clinical trials for individuals with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia and B-cell malignancies. Additionally, CLR 131 is being studied in Phase 2B for r/r multiple myeloma (MM) and in Phase I trials targeting a range of pediatric cancers, r/r head and neck cancers, and R/R MM. Furthermore, Cellectar is advancing CLR 1900, another PDC-based chemotherapeutic program, which is in preclinical stages with the aim of treating solid tumors. The firm also participates in collaborative PDC development initiatives with partners such as Avicenna Oncology GMBH for the CLR 2000 Series, Orano Med for the CLR 12120 Series, as well as IntoCell Inc. and LegoChemBio. Established in 2002, Cellectar Biosciences maintains its corporate headquarters in Florham Park, New Jersey.
Show more...
CEO
Mr. James V. Caruso
Employees
11
Country
United States
ISIN
US15117F8804

Listings

F
DE
NV40.F
STU
DE
NV40.STU
MU
DE
NV40.MU
XNAS
US
CLRB

0 Comments

Share your thoughts

FAQ

What is Cellectar Biosciences stock price today?▼
The current price of CLRB is $2.34 USD — it has increased by +4.93% in the past 24 hours. Watch Cellectar Biosciences stock price performance more closely on the chart.
What is Cellectar Biosciences stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Cellectar Biosciences stocks are traded under the ticker CLRB.
Is Cellectar Biosciences stock price growing?▼
CLRB stock has fallen by -0.85% compared to the previous week, the month change is a -24.27% fall, over the last year Cellectar Biosciences has showed a +512.24% increase.
What is Cellectar Biosciences market cap?▼
Today Cellectar Biosciences has the market capitalization of 7.47M
When is the next Cellectar Biosciences earnings date?▼
Cellectar Biosciences is going to release the next earnings report on August 19, 2026.
What were Cellectar Biosciences earnings last quarter?▼
CLRB earnings for the last quarter are -1.33 USD per share, whereas the estimation was -1.89 USD resulting in a +29.44% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Cellectar Biosciences revenue for the last year?▼
Cellectar Biosciences revenue for the last year amounts to 0 USD.
What is Cellectar Biosciences net income for the last year?▼
CLRB net income for the last year is -89.16M USD.
How many employees does Cellectar Biosciences have?▼
As of June 16, 2026, the company has 11 employees.
In which sector is Cellectar Biosciences located?▼
Cellectar Biosciences operates in the Health & Wellness sector.
When did Cellectar Biosciences complete a stock split?▼
The last stock split for Cellectar Biosciences was on June 24, 2025 with a ratio of 1:30.
Where is Cellectar Biosciences headquartered?▼
Cellectar Biosciences is headquartered in Florham Park, United States.